Publications by the researcher in collaboration with Bonaventura Clotet Sala (20)

2018

  1. Real world patient-reported outcomes in HIV-infected adults switching to EVIPLERA®, because of a previous intolerance to cART. PRO-STR study

    Current HIV Research, Vol. 16, Núm. 6, pp. 425-435

2017

  1. Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253

2016

  1. Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe

    Clinical Infectious Diseases, Vol. 62, Núm. 5, pp. 655-663

2015

  1. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784

  2. Primary resistance to integrase strand-transfer inhibitors in Europe

    Journal of Antimicrobial Chemotherapy, Vol. 70, Núm. 10, pp. 2885-2888

2014

  1. Documento de consenso de GeSIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (Actualización enero 2014)

    Enfermedades Infecciosas y Microbiologia Clinica Monografias, Vol. 32, Núm. 7, pp. 446e1-446e42

  2. Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014)

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 32, Núm. 7, pp. 447-458

  3. Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe

    BMC Infectious Diseases, Vol. 14, Núm. 1

2013

  1. Limited cross-border infections in patients newly diagnosed with HIV in Europe

    Retrovirology, Vol. 10, Núm. 1

  2. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies

    AIDS, Vol. 27, Núm. 1, pp. 81-85

2012

  1. Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy

    Retrovirology, Vol. 9

  2. Mutations in the protease gene associated with virological failure to lopinavir/ritonavir-containing regimens

    Journal of Antimicrobial Chemotherapy, Vol. 67, Núm. 6, pp. 1462-1469

2010

  1. El papel de las combinaciones de antirretrovirales a dosis fijas en el tratamiento de la infeccin por VIH-1

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 28, Núm. 9, pp. 615-620

2009

  1. (Enfermedades Infecciosas y Microbiologia Clinica (2009) 27, 4, (222-235))

    Enfermedades Infecciosas y Microbiologia Clinica

  2. HIV-1 reverse transcriptase thumb subdomain polymorphisms associated with virological failure to nucleoside drug combinations

    Journal of Antimicrobial Chemotherapy, Vol. 64, Núm. 2, pp. 251-258

  3. The changing face of HIV/AIDS in treated patients

    Current HIV Research, Vol. 7, Núm. 4, pp. 365-377

2008

  1. Long-distance interactive expert advice in highly treatment-experienced HIV-infected patients

    Journal of Antimicrobial Chemotherapy, Vol. 61, Núm. 1, pp. 206-209

  2. Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: A multicentre pilot study

    HIV Medicine, Vol. 9, Núm. 7, pp. 508-513

2005

  1. Antiretroviral treatment simplification with 3 NRTIs or 2 NRTIs plus nevirapine in HIV-1-infected patients treated with successful first-line HAART

    Journal of Acquired Immune Deficiency Syndromes, Vol. 39, Núm. 3, pp. 313-316

2004

  1. Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach

    Antiviral Therapy, Vol. 9, Núm. 3, pp. 335-342